Catalyst Pharmaceuticals, Inc.
CPRXNASDAQHealthcare● Active
$31.28
+$0.01(+0.04%)
Market Cap$3.8B
P/E Ratio—
52W High$32.56
52W Low$19.05
Catalyst Pharmaceuticals, Inc. (CPRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CPRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.59B | $0.49B | $0.40B | $0.21B | $0.14B |
| Cost of Revenue | $0.09B | $0.07B | $0.05B | $0.03B | $0.02B |
| Gross Profit | $0.50B | $0.42B | $0.35B | $0.18B | $0.12B |
| Gross Margin %(computed) | 85.19% | 86.00% | 86.95% | 83.94% | 84.46% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.09B | $0.02B | $0.02B |
| G&A Expenses | $0.07B | $0.17B | $0.05B | $0.05B | $0.02B |
| Total Operating Expenses | $0.24B | $0.23B | $0.26B | $0.08B | $0.07B |
| Operating Income | $0.26B | $0.20B | $0.09B | $0.10B | $0.05B |
| Operating Margin %(computed) | 43.77% | 39.68% | 21.80% | 47.54% | 37.20% |
| Interest Income | $0.00B | $0.02B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.28B | $0.22B | $0.09B | $0.10B | $0.05B |
| Income Tax Expense | $0.07B | $0.05B | $0.02B | $0.02B | $0.01B |
| Net Income | $0.21B | $0.16B | $0.07B | $0.08B | $0.04B |
| Net Margin %(computed) | 36.39% | 33.33% | 17.93% | 38.79% | 28.03% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.75 | $1.38 | $0.67 | $0.80 | $0.38 |
| Wtd Avg Shares | 0.12B | 0.12B | 0.11B | 0.10B | 0.10B |
| EBITDA | $0.30B | $0.23B | $0.12B | $0.10B | $0.05B |
| EBITDA Margin %(computed) | 50.20% | 47.36% | 30.06% | 48.12% | 37.33% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Catalyst Pharmaceuticals, Inc. data
About Catalyst Pharmaceuticals, Inc. (CPRX) Income Statement
Catalyst Pharmaceuticals, Inc. (CPRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CPRX reported revenue of $0.59B, gross profit of $0.50B (gross margin 85.19%), and net income of $0.21B — a net profit margin of 36.39%.
Frequently asked questions
CPRX · 4 questionsCatalyst Pharmaceuticals, Inc. (CPRX) reported revenue of $0.59B for 2025, up 19.8% year-over-year.
CPRX revenueCPRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08